TransMedics Group, Inc. (NASDAQ:TMDX) Position Raised by Quantbot Technologies LP

Quantbot Technologies LP increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 601.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,738 shares of the company’s stock after purchasing an additional 16,926 shares during the period. Quantbot Technologies LP owned 0.06% of TransMedics Group worth $3,099,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMDX. International Assets Investment Management LLC bought a new stake in TransMedics Group during the second quarter worth approximately $47,000. USA Financial Formulas bought a new position in shares of TransMedics Group in the third quarter valued at $55,000. J.Safra Asset Management Corp increased its holdings in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC increased its holdings in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

TMDX opened at $87.11 on Thursday. The firm has a market capitalization of $2.92 billion, a P/E ratio of 92.67 and a beta of 2.08. The stock’s 50 day moving average price is $114.84 and its two-hundred day moving average price is $136.79. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $67.77 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the business earned ($0.12) EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analysts Set New Price Targets

TMDX has been the topic of several research reports. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating and set a $109.00 price target on shares of TransMedics Group in a research report on Friday, November 22nd. JPMorgan Chase & Co. reduced their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Robert W. Baird reduced their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Finally, Stephens increased their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $131.80.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This trade represents a 12.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,958 shares of company stock valued at $3,470,328. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.